Results 141 to 150 of about 1,988,593 (307)

Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm, Lyn D. Ferguson, Iain B. McInnes   +2 more
wiley   +1 more source

The synergistic impact of granulocytic myeloid‐derived suppressor cells and innate lymphoid cells in systemic sclerosis

Arthritis &Rheumatology, Accepted Article.
Objective Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by immune dysregulation and fibrosis, with myeloid‐derived suppressor cells (MDSCs) emerging as important regulators of immune responses. However, the role of MDSCs in SSc‐associated fibrosis and their interactions with other immune cell populations remain poorly ...
Stefanie Weber, Mario R. Angeli, Hashem Mohammadian, Hannah Labinsky, Maria Gabriella Raimondo, Richard Demmler, Yuko Ariza, Thomas Wohlfahrt, Markus Luber, Yi‐Nan Li, Jörg H.W. Distler, Tobias Bäuerle, Georg Schett, Simon Rauber, Andreas Ramming, Alina M. Ramming   +15 more
wiley   +1 more source

Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.

, 2004
Imatinib is a tyrosine-kinase inhibitor that binds to ABL proteins and induces cytogenetic remissions in patients with chronic myeloid leukemia (CML). In these patients measuring response by molecular techniques is clearly required.
ALBERTI D, ITALIAN COOPERATIVE STUDY GROUP FOR CHRONIC MYELOID L.E.U.K.E.M.I.A., BASSI S, SOVERINI S, ITALIAN COOPERATIVE STUDY GROUP FOR CHRONIC MYELOID LEUKEMIA, SOVERINI, SIMONA, ROSTI, GIANANTONIO, BASSI, SIMONA, CILLONI D., DE VIVO, ANTONIO, SALVATORE F., GIANNINI B, ALBERTI D., AMABILE, MARILINA, TRABACCHI E, ROSTI G, AMABILE M, BONIFAZI, FRANCESCA, TRABACCHI E., BACCARANI M, TESTONI, NICOLETTA, LUATTI S, GIANNINI B., BONIFAZI F, ITALIAN COOPERATIVE STUDY GROUP ON CHRONIC MYELOID LEUKEMIA, BACCARANI, MICHELE, DE VIVO A, MARTINELLI G, CAMBRIN GR, WRITING COMMITTEE, STUDY COMMITTEE, CAMBRIN G. R., MARTINELLI, GIOVANNI, PANE F., PANE, FABRIZIO, CILLONI D, SALVATORE F, SAGLIO G, LUATTI, SIMONA, IZZO, BARBARA, IZZO B., TESTONI N, GOTTARDI E, GOTTARDI E., SAGLIO G.   +44 more
core   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Hypoxic conditions confer chemoresistance to crizotinib but not to imatinib in chronic myeloid leukemia cells

Hematology, Transfusion and Cell Therapy
Introduction: Chronic myeloid leukemia is an adult leukemia, constituting 15 % of all leukemia diagnoses. The fundamental driver of disease pathogenesis is the Bcr/Abl fusion protein, characterized by dysregulated tyrosine kinase activity.
Lena Avinery, Danielle Regev, Hazem Khamaisi, Jacob Gopas, Jamal Mahajna   +4 more
doaj   +1 more source

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up (on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia)

, 2008
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungolino E, Rege-Cambrin G ...
ALBERTI D, BASSI S, ALIMENA G, BRECCIA, M, SPECCHIA, Giorgina, MARZOCCHI G, ROSTI G., VARALDO R, SPECCHIA G, BOCCHIA, MONICA, BOCCHIA M, ROSTI G, BACCARANI M, LUATTI S, PALANDRI F, MARTINELLI G, BRECCIA M, GIMEMA WORKING PARTY ON CHRONIC MYELOID LEUKEMIA, MIGLINO, MAURIZIO, MARTINELLI, GIOVANNI, MIGLINO M, CASTAGNETTI F, SAGLIO G, ALIMENA, Giuliana, REGE CAMBRIN G, PANE F, TESTONI N, PUNGOLINO E, FERRARA F, ZUFFA E   +29 more
core   +1 more source

Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen, Mathilde Rønne Koch, Cecilie Utke Rank, Christen Lykkegaard Andersen, Allan Weimann, Maria Thastrup, Tianwu Yang, Trine Meldgaard Lund, Ib Jarle Christensen, Flemming Nielsen, Tore Bjerregaard Stage, Sara Bisgaard Jensen, Mette Klarskov Andersen, Kjeld Schmiegelow, Kim Dalhoff   +14 more
wiley   +1 more source

Leukemia and risk of stroke: a Mendelian randomization analysis

BMC Neurology
Background Observational studies suggest an association between leukemia and stroke, but causality remains unclear. Certain leukemia types may increase stroke risk, but variations exist in stroke and mortality rates across leukemia subtypes.
Xiaoyao Yi, Jingrui Zhu, Xiang Zhang, Ning Huang, Yuan Cheng   +4 more
doaj   +1 more source

Treatment-free remission in patients with chronic myeloid leukemia

, 2020
Chronic myeloid leukemia is a disease that affects about 1.9 in every 100 000 people annually and represents 15% of all new cases of leukemia in the West. Survival rates in CML have dramatically increased since the advent of TKIs.
Okoh, Nelson
core  

Relationship between continuous infusion meropenem PK/PD target attainment and C‐reactive protein dynamics in onco‐haematologic patients with febrile neutropenia

British Journal of Clinical Pharmacology, EarlyView.
Aim Meropenem is a second‐line antimicrobial agent in the treatment of febrile neutropenia in onco‐haematological patients. A population pharmacokinetic/pharmacodynamic (PK/PD) analysis for assessing the relationship between meropenem exposure and C‐reactive protein (C‐RP) over time was conducted.
Chun Liu, Pier Giorgio Cojutti, J. G. Coen van Hasselt, Michele Bartoletti, Maddalena Giannella, Pierluigi Zinzani, Pierluigi Viale, Federico Pea   +7 more
wiley   +1 more source